PREVENZIONE DEL DANNO DA FANS: ARRIVA LA REBAMIPIDE! LA PRIMA REVISIONE SISTEMATICA CON META-ANALISI. DA “American Journal of Gastroenterology”

GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, NEWSLETTER

Efficacy of Rebamipide in the Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Mucosal Breaks: A Systematic Review and Meta-Analysis Cion, Rochelle Ivy A. MD; Juyad, Ian Gabriel A. MD; Yasay, Eric B. MD INTRODUCTION: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most used medications worldwide. A major limitation of these drugs is gastrointestinal (GI) mucosal injury. Several…

COME POTREBBERO FUNZIONARE I VACCINI A BASE mRNA PER LA TERAPIA DEL CANCRO? UNA GRANDE ANALISI DA RITA RUBIN. DA “JAMA” (FREE)

CHIRURGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, INTERNATIONAL SNAPSHOTS, NEWSLETTER, ONCOLOGIA, PANCREAS E VIE BILIARI

How mRNA Vaccines Could Help Treat Cancer Rita Rubin, MA Malignant tumors are sneaky. They tend to fly under the immune system’s radar because, unlike invaders such as viruses or bacteria, cancer cells arise from normal cells, so they bear many of the same familiar molecules on their surface. (opens in new tab) Once tumors…

COLITE ULCEROSA: COSA FARE SE VEDOLIZUMAB NON FUNZIONA? UN OTTIMO STUDIO DI COORTE DA “GETAID” SULLA SECONDA LINEA DI TRATTAMENTO. DA “UEG JOURNAL” (FREE)

GASTROENTEROLOGIA, IBD, METODOLOGIA, NEWSLETTER

Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID Louis Calméjane et al for GETAID ABSTRACT Background and Aims Vedolizumab has become the preferred first-line advanced therapy in ulcerative colitis (UC). However, the optimal second-line treatment following vedolizumab failure remains unclear. We aimed to evaluate…

EHILA’! QUALCHE CONSIGLIO PER LEGGERE VELOCEMENTE UN NUOVO TRIAL? LASCIATE PARLARE BISHAL GYAWALI! ARTICOLO MONSTRE! DA”JCO ONCOLOGY PRACTICE” (FREE)

GASTROENTEROLOGIA, METODOLOGIA, NEWSLETTER, ONCOLOGIA

How I Read a Clinical Trial Report? A Primer for Busy Clinicians  Bishal Gyawali, MD, PhD, FASCO  Reading a clinical trial report with a critical lens requires some skills and training. Unfortunately, these skills are not often taught during residency or fellowship. In this study, I will discuss my approach to critical appraisal of a cancer clinical…

COLANGITE SCLEROSANTE PRIMITIVA VS IgG4 CORRELATA : UNA IMPORTANTE REVISIONE CON META-ANALISI SU 38 STUDI. OCCHIO ALLA COPRESENZA DI PATOLOGIA PANCREATICA! DA”THE AMERICAN J. OF GASTROENTEROLOGY”

CHIRURGIA, EPATOLOGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA, PANCREAS E VIE BILIARI

Differentiating IgG4-related Sclerosing Cholangitis from Primary Sclerosing Cholangitis: A Comprehensive Systematic Review and Meta-analysis of Diagnostic Features Wang, Mark et al. Introduction: Immunoglobulin G4–related sclerosing cholangitis (IgG4-SC) and primary sclerosing cholangitis (PSC) are cholestatic disorders which may be difficult to differentiate. Importantly, PSC is an untreatable progressive fibroinflammatory disease, whereas IgG4-SC responds to immunosuppression if…

CANCRO DEL RETTO: L’ESCISSIONE DEL MESORETTO PER VIA TRANSANALE E’ COMPARABILE NEL BREVE TERMINE ALLA ESCISSIONE LAPAROSCOPICA . UN TRIAL IMPORTANTE MULTICENTRICO SU 1.200 PAZIENTI. DA”THE LANCET”

CHIRURGIA, ECOGRAFIA ED ECOENDOSCOPIA, ENDOSCOPIA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA

Lo studio COLOR III è un trial internazionale, multicentrico, randomizzato e controllato di fase 3 che confronta l’escissione mesoretto totale transanale (TaTME) con quella laparoscopica (LapTME) in pazienti con adenocarcinoma rettale medio-basso. L’obiettivo primario è la recidiva locale a 3 anni, mentre qui si riportano gli esiti secondari a breve termine. Sono stati arruolati 1103…